Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.37 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31260325 | 0.86 | TSHR (0.50) | TSHRTDP1CYP3A4ATMALDH1A1 | |
| SCHEMBL10239305 | 0.86 | CYP3A4 (0.46) | TSHRTDP1CYP3A4ATMALDH1A1 | |
| SCHEMBL1390827 | 0.84 | ALDH1A1 (0.46) | TSHRTDP1CYP3A4ATMALDH1A1 | |
| SCHEMBL31260295 | 0.84 | CYP3A4 (0.43) | TSHRTDP1CYP3A4ATMALDH1A1 | |
| SCHEMBL31260310 | 0.83 | TDP1 (0.42) | TSHRTDP1CYP3A4ATMALDH1A1 | |
| SCHEMBL19259864 | 0.82 | TDP1 (0.46) | TSHRTDP1CYP3A4ATMALDH1A1 | |
| SCHEMBL31260394 | 0.81 | CYP3A4 (0.45) | TSHRTDP1CYP3A4ATMALDH1A1 | |
| SCHEMBL10239258 | 0.81 | CYP3A4 (0.46) | TSHRTDP1CYP3A4ATMALDH1A1 | |
| SCHEMBL9114266 | 0.81 | TDP1 (0.40) | TSHRTDP1CYP3A4ATMALDH1A1 | |
| SCHEMBL1390971 | 0.81 | CYP3A4 (0.40) | TSHRTDP1CYP3A4ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4716685-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070906-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| WO-2024240726-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070906-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | TLR1, TLR6, TLR8 | TSHR 1070/4885TDP1 2181/4885CYP3A4 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.